Roger Jeffs, Chief Executive Officer of Liquidia Corp (NASDAQ:LQDA), sold a total of 75,000 shares of the company’s common stock for approximately $4.42 million over three trading days in mid-May, according to a recent Form 4 filing with the Securities and Exchange Commission. The transactions were executed under a Rule 10b5-1 trading plan established on November 5, 2025.
The sales occurred on May 18, May 19, and May 20, 2026. On May 18, Mr. Jeffs disposed of 25,000 shares at a volume-weighted average price of $56.7728. Another 25,000 shares were sold on May 19 at an average price of $58.6457. The final 25,000 shares were sold on May 20 at an average price of $61.3019. The total value for these sales was $4,418,010.
The timing of these sales coincides with Liquidia trading near its 52-week high of $62.17, following a remarkable 263% return over the past year. The stock currently trades at $61.77 with a market capitalization of $5.49 billion.
The shares sold were held indirectly by Serendipity BioPharma LLC, where Mr. Jeffs serves as a manager. Following these transactions, Serendipity BioPharma LLC holds 1,123,095 shares of Liquidia common stock, representing a significant ongoing stake in the company.
Mr. Jeffs also directly holds 1,137,508 shares of common stock, which includes various tranches of unvested restricted stock units. Additionally, 46,595 shares are held indirectly by the Roger A. Jeffs Living Trust.
In other recent news, Liquidia Technologies reported first-quarter revenue of approximately $130 million, surpassing consensus estimates of $114 million. Analysts from Jefferies, BTIG, and Raymond James have all raised their price targets for Liquidia, citing the strong performance of their drug Yutrepia.
